

SUPPLEMENTARY MATERIAL

Supplementary Table 1: Characteristics of the Study Population by Quartiles of High Molecular Weight Adiponectin

Quartile (n)	Q1 (798)	Q2 (797)	Q3 (798)	Q4 (797)
Adiponectin, mg/l	<3.8	3.8-6.2	>6.2-9.9	>9.9
Age, years	73±5	74±4	75±5	76±6
Men, n (%)	470 (58.9)	334 (41.9)	226 (28.3)	129 (16.2)
African-American, n (%)	241 (30.2)	128 (16.1)	80 (10.0)	75 (9.4)
Education < high school, n (%)	231 (28.9)	212 (26.6)	188 (23.6)	176 (22.1)
BMI, kg/m ²	28.7±4.7	27.5±4.5	26.6±4.7	24.6±4.1
Height, cm	167±9	165±9	163±9	160±8
Weight, kg	177±31	165±29	155±30	139±27
Systolic blood pressure, mmHg	136±21	137±21	137±21	135±20
Diastolic blood pressure, mmHg	73±11	73±11	72±11	71±11
Anti-hypertensive medication, n (%)	357 (44.7)	350 (43.9)	309 (38.7)	261 (32.7)
Diabetes, n (%)	201 (25.6)	82 (10.5)	64 (8.1)	38 (4.9)
HOMA-IR	6.2±11.6	3.5±4.4	3.0±6.7	2.2±2.3
LDL, mg/dl	126±35	128±33	130±33	125±34

HDL, mg/dl	47±12	51±12	56±13	64±15
Triglyceride (mg/dl)	143 (102, 205)	131 (95, 180)	120 (89, 160)	98 (73, 133)
Lipid-lowering medication, n (%)	54 (6.8)	60 (7.5)	47 (5.9)	37 (4.6)
Current smoker, n (%)	92 (11.5)	78 (9.8)	90 (11.3)	74 (9.3)
Alcohol use ≥7 drinks/week, n (%)	90 (11.3)	103 (12.9)	107 (13.4)	121 (15.2)
Estrogen replacement (women), n (%)	34 (4.3)	68 (8.5)	84 (10.5)	107 (13.4)
ACE inhibitor medication, n (%)	87 (10.9)	72 (9.0)	65 (8.1)	43 (5.4)
Beta-blocker medication, n (%)	99 (12.4)	73 (9.2)	61 (7.6)	32 (4.0)
Self-reported health fair/poor, n (%)	130 (16.3)	109 (13.7)	110 (13.8)	130 (16.3)
Unintentional weight loss >10 lbs, n (%)	34 (4.6)	25 (3.5)	30 (4.1)	47 (6.6)
eGFR, ml/min/m ^{1.73}	75±19	74±17	74±17	77±19
hsCRP, mg/l	3.4 (1.7, 6.5)	2.8 (1.3, 5.9)	2.2 (1.1, 5.4)	1.6 (0.8, 3.6)
NT-proBNP ₁₋₇₆ , ng/l	70 (40, 134)	99 (59, 179)	132 (74, 232)	168 (98, 286)
Subclinical CVD, n (%)	527 (67.6)	496 (63.7)	470 (60.6)	465 (60.2)
High LA diameter index†, n (%)	33 (5.0)	40 (6.0)	35 (5.4)	69 (11.0)
Low LVEF (<55%)†, n (%)	43 (6.8)	36 (5.6)	32 (5.0)	39 (6.3)
Transmitral E/A ratio†, n (%)				
<0.7	156 (23.7)	174 (26.3)	161 (25.0)	120 (19.4)

0.7-1.5	490 (74.5)	470 (71.1)	470 (73.10)	478 (77.2)
>1.5	12 (1.8)	17 (2.6)	12 (1.9)	21 (3.4)
Incident AF, n (%)	206 (25.8)	216 (27.1)	235 (29.4)	229 (28.7)
Incident HF before AF, n (%)	170 (21.3)	157 (19.7)	149 (18.7)	143 (17.9)
Incident CHD before AF, n (%)	242 (30.3)	216 (27.1)	203 (25.4)	161 (20.2)

*Continuous values as presented as means±SD or as medians (interquartile range).

ACE, angiotensin converting enzyme; AF, atrial fibrillation; BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HDL, high density lipoprotein; HOMA-IR, homeostasis model assessment–insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL, low density lipoprotein; LA, left atrial; LVEF, left ventricular ejection fraction; NT-proBNP₁₋₇₆, amino-terminal pro-B-type natriuretic peptide 1-76; wt, weight.

†Obtained 2 years after the 1992-93 baseline (i.e., at the 1994-95 examination)